Key result
Levosimendan compared with milrinone did not significantly reduce postoperative serum creatinine (p=0.65) or acute kidney injury (46.9% vs 39.5%, p=0.70) in infants after congenital heart surgery.
Why the study?
Unlike other inotropic agents, levosimendan improves glomerular filtration rate after adult cardiac surgery, but its efficacy versus milrinone in preventing acute kidney dysfunction in infants undergoing open-heart surgery with cardiopulmonary bypass was unstudied.
Does levosimendan prevent acute kidney dysfunction compared to milrinone in infants undergoing open-heart surgery with cardiopulmonary bypass?
RCT (n=72)
Double-blind
randomized
Yes
Does levosimendan prevent acute kidney dysfunction compared to milrinone in infants undergoing open-heart surgery with cardiopulmonary bypass?
p-value: p=0.65
In infants undergoing corrective congenital heart surgery, a perioperative infusion of levosimendan did not reduce the occurrence of acute kidney injury compared with milrinone.
Levosimendan does not reduce acute kidney injury versus milrinone after infant congenital heart surgery; challenges adult renal benefit data and leaves optimal inotrope choice open.
OBJECTIVES: It has been shown that, in contrast to other inotropic agents, levosimendan improves glomerular filtration rate after adult cardiac surgery. The aim of this study was to investigate the efficacy of levosimendan, compared with milrinone, in preventing acute kidney dysfunction in infants after open-heart surgery with cardiopulmonary bypass. DESIGN: Two-center, double-blinded, prospective, randomized clinical trial. SETTING: The study was performed in two tertiary pediatric centers, one in Sweden (Gothenburg) and one in Finland (Helsinki). PATIENTS: Infants between 1 and 12 months old, diagnosed with Tetralogy of Fallot, complete atrioventricular septal defect or nonrestrictive ventricular septal defect, undergoing total corrective cardiac surgery with cardiopulmonary bypass. INTERVENTIONS: Seventy-two infants were randomized to receive a perioperative infusion of levosimendan (0.1 µg/kg/min) or milrinone (0.4 µg/kg/min). The infusion was initiated at the start of cardiopulmonary bypass and continued for 26 hours. MEASUREMENTS AND MAIN RESULTS: The primary outcome variable was the absolute value of serum creatinine data on postoperative day 1. Secondary outcomes included the following: 1) acute kidney injury according to the serum creatinine criteria of the Kidney Diseases: Improving Global Outcomes; 2) acute kidney injury with serum creatinine corrected for fluid balance; 3) plasma neutrophil gelatinase-associated lipocalin; 4) cystatin C; 5) urea; 6) lactate; 7) hemodynamic variables; 8) use of diuretics in the PICU; 9) need of dialysis; 10) length of ventilator therapy; and 11) length of PICU stays. There was no significant difference in postoperative serum creatinine between the treatment groups over time (p = 0.65). The occurrence rate of acute kidney injury within 48 hours was 46.9% in the levosimendan group and 39.5% in the milrinone group (p = 0.70). There were no significant differences in other secondary outcome variables between the groups. CONCLUSIONS: Levosimendan compared with milrinone did not reduce the occurrence rate of acute kidney injury in infants after total corrective heart surgery for atrioventricular septal defect, ventricular septal defect, or Tetralogy of Fallot.
No takes yet. Share an insight, caveat, or question.
Thorlacius et al. (2019) conducted an RCT in Congenital heart defects requiring surgery (n=72). Levosimendan vs. Milrinone was evaluated on absolute value of serum creatinine data on postoperative day 1 (p=0.65). Levosimendan compared with milrinone did not significantly reduce postoperative serum creatinine (p=0.65) or acute kidney injury (46.9% vs 39.5%, p=0.70) in infants after congenital heart surgery.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: